Abstract
End-stage kidney disease (ESKD) is an expensive condition to manage in contemporary health care for the healthcare provider, patient and family [1]. People affected by ESKD usually require kidney replacement therapy in the form of dialysis or kidney transplantation to survive [2]. Projections of the prevalence of those requiring treatment of ESKD will rise by 60%-from 19,780 cases in 2011 to 31,589 cases in 2020 [3] in Australia.
Original language | English |
---|---|
Pages | 1-13 |
Number of pages | 13 |
Publication status | Unpublished - 2019 |